Beta Bionics, Inc. Common Stock (BBNX)

• Market cap: $781M
• 1 day: 2.92%
• 5 days: 13.60%
• 1 month: 28.38%
• 3 months: 20.13%
• 6 months: -10.16%
• Year to date: -23.99%
• 1 year: -23.99%
• 5 years: -23.99%
• 10 years: -23.99%
• Sector: Healthcare
• Industry: Medical Devices

About: Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.

Employees: 392

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

93% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 14

30% more capital invested

Capital invested by funds: $508M [Q1] → $659M (+$151M) [Q2]

29% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 28

11% more funds holding

Funds holding: 103 [Q1] → 114 (+11) [Q2]

7.21% more ownership

Funds ownership: 96.2% [Q1] → 103.41% (+7.21%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $16 11% downside
• Avg. target: $21 16% upside
• High target: $30 67% upside

5 analyst ratings

• positive: 3 60%
• neutral: 2 40%
• negative: 0 0%

Truist Securities Richard Newitter	17% upside $21	Buy Maintained	30 Jul 2025
Baird Jeff Johnson	5% downside $17	Neutral Maintained	30 Jul 2025
Lake Street Frank Takkinen	67% upside $30	Buy Assumed	12 Jun 2025
Goldman Sachs David Roman	11% downside $16	Neutral Initiated	30 May 2025
Wolfe Research Mike Polark	11% upside $20	Outperform Initiated	30 May 2025